Introduction: 5-10% of cancer diagnoses occur due to a significant inherited genetic susceptibility, but referrals for individuals with a personal/family history of cancer account for ~45% of referrals to Clinical Genetics. Confirming cancer/genetic diagnoses is essential to provide an accurate risk assessment, assess eligibility for genetic testing and make recommendations for cancer surveillance. Previously, triage decisions were based on limited referral information, resulting in unnecessary appointments. Our pathway was developed to collate relevant clinical information following initial triage with subsequent re-triage resulting in an appointment or referral closure with detailed assessment provided by letter.

Methods: We assessed the re-triage pathway over 12-months (March 2024-2025). Outcomes were categorised as ‘closure letter’ or ‘appointment’. The review assessed referral types, outcomes, and impact on patient care and service delivery.

Results: 221/387 patients were sent closure letters with a comprehensive cancer risk assessment. Among closures, 28% (n=87) were recommended additional cancer screening;25% (n=79) were within population risk and reassured. Closure letters were sent 3.4 months post-referral on average. 166 received appointments;53% (n=96) were eligible for either diagnostic (n=22) or predictive (n=74) genetic testing.